



Evidence reviews - March 2026

Evidence review

Published: 19 March 2026

www.nice.org.uk

The following documents contain the evidence that was used to develop the 2026 recommendations:

- [Management of localised renal cell carcinoma using partial versus radical nephrectomy](#)
- [Management of localised renal cell carcinoma using non-surgical interventions or active surveillance](#)
- [Management of locally advanced renal cell carcinoma using nephrectomy or stereotactic ablative radiotherapy](#)
- [Information needs](#)
- [Monitoring of untreated renal lesions using active surveillance](#)
- [Follow-up of previously treated renal cell carcinoma](#)
- [Genetic assessment and management of renal cell carcinoma \(RCC\) associated with heritable RCC syndromes](#)
- [Management of advanced renal cell carcinoma using non-pharmacological interventions](#)
- [CT and MRI for diagnosing renal lesions in adults with suspected renal cell carcinoma](#)
- [Additional imaging tests for differentiating types of renal lesions](#)
- [Renal biopsy](#)
- [Risk prediction tools for localised and locally advanced renal cell carcinoma](#)
- [Risk prediction tools for metastatic renal cell carcinoma](#)

Other supporting evidence

- [Methods](#)
- [Economic analysis report on management of localised renal cell carcinoma using non-surgical interventions or active surveillance](#)
- [Economic model report for follow up and monitoring for previously treated renal cell carcinoma](#)